Bavarian Nordic A/S
CSE:BAVA
Bavarian Nordic A/S
Total Receivables
Bavarian Nordic A/S
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Receivables
kr1.2B
|
CAGR 3-Years
40%
|
CAGR 5-Years
78%
|
CAGR 10-Years
19%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Receivables
kr6.7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
51%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Receivables
kr291m
|
CAGR 3-Years
38%
|
CAGR 5-Years
79%
|
CAGR 10-Years
24%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Receivables
€177.4m
|
CAGR 3-Years
97%
|
CAGR 5-Years
101%
|
CAGR 10-Years
54%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Receivables
kr17.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Saniona AB
STO:SANION
|
Total Receivables
kr15m
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
Bavarian Nordic A/S
Glance View
Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.
See Also
What is Bavarian Nordic A/S's Total Receivables?
Total Receivables
1.2B
DKK
Based on the financial report for Dec 31, 2024, Bavarian Nordic A/S's Total Receivables amounts to 1.2B DKK.
What is Bavarian Nordic A/S's Total Receivables growth rate?
Total Receivables CAGR 10Y
19%
Over the last year, the Total Receivables growth was -33%. The average annual Total Receivables growth rates for Bavarian Nordic A/S have been 40% over the past three years , 78% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet